Drug Trial Radar · NCT07869836
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- SystImmune Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
Conditions
- Urothelial Cancer
- Metastatic Urothelial Cancer
- Bladder Cancer
- Bladder Cancer (BC)
- Bladder (Urothelial, Transitional Cell) Cancer
- Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
- Bladder Ca
- Bladder Cancer Recurrent
- Bladder Cancer Stage IV
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Recurrent
- Urothelial Carcinoma of the Urinary Bladder
Interventions
T-Bren, Dose level 1Drug
T-bren: Administered intravenously on day 1 of each 21-day cycle
T-bren, Dose level 2Drug
TBren administered intravenously on day 1 of each 21-day cycle
Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)Drug
Gemcitabine administered intravenously on Day 1 and Day 8 of each 21-day cycle and Cisplatin or Carboplatin administered intravenously on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Approximately 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Central Georgia Cancer Center
Macon, Georgia · Recruiting
(AOR) Hawaii Cancer Care
‘Aiea, Hawaii · Recruiting
(AOR) Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.